https://www.selleckchem.com/products/rp-6306.html
The three part, double-blind, randomized, controlled reSURFACE 1 trial and extension study (NCT01722331) evaluated efficacy and safety of tildrakizumab in adults with moderate to severe plaque psoriasis. Patients with ≥50% improvement from baseline in Psoriasis Area and Severity Index (PASI 5 following treatment with tildrakizumab 100 mg (TIL10 or 200 mg (TIL20 could enter the optional long-term extension study and continue treatment at the same dose for an additional 192 weeks. This subgroup analysis assessed the long-term effica
Like
Comment
Share
